ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HCM Hutchmed (china) Limited

304.00
-6.00 (-1.94%)
Last Updated: 09:35:59
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.00 -1.94% 304.00 304.00 314.00 311.00 303.00 311.00 4,563 09:35:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 838M 100.78M - N/A 0
Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 310p. Over the last year, Hutchmed (china) shares have traded in a share price range of 173.60p to 338.00p.

Hutchmed (china) currently has 871,256,270 shares in issue.

Hutchmed (china) Share Discussion Threads

Showing 551 to 568 of 4100 messages
Chat Pages: Latest  32  31  30  29  28  27  26  25  24  23  22  21  Older
DateSubjectAuthorDiscuss
26/3/2013
11:35
Some bullish remarks from the CEO on today's results. The bit saying that the company expects to "create substantial shareholder value in 2013/2014 and the years beyond" certainly sounds optimistic.

"2012 has been a great year for Chi-Med. In particular, our Drug R&D operation and its potential have been transformed through our 50/50 joint venture with Nestlé Health Science, which followed our 2011 deal with AstraZeneca, and by the rapidly expanding programme of discovery, clinical trial proof-of-concept data and licensing dialogue. The significant value of its pipeline of compounds is becoming increasingly clear."

"The Drug R&D Division is now beginning to demonstrate that its innovations are of considerable worth and consequently we expect other partnership deals in 2013. We expect to create substantial shareholder value in 2013/2014 and the years beyond."

protean
07/3/2013
18:34
looks ready for 700p target
snatander
30/11/2012
10:25
Someone accumulating here. Big trades last few days continuing and the share price not budging. Bodes verrrry well cos this is narrowly traded. Expect a move up Monday. Hoping Midas cover it too at weekend
john09
29/11/2012
19:44
glad i added
gucci
29/11/2012
07:50
should be 6 quid this
daveycaferacer
28/11/2012
11:00
about time as well!
daveycaferacer
28/11/2012
10:52
breaking out
gucci
28/11/2012
08:07
Excellent announcement and about to fly this.
john09
18/10/2012
23:00
From a couple of months back, but worth reading. Mark Slater has a good track record and this is one of his top holdings.



Some buying interest today pushing price near to potential breakout territory.

protean
18/10/2012
22:47
The HMPL-004 deal is already in the public domain- in the accounts- will be concluded b4 y/e. And if you think director's don't know what's going on in the company and when - you're seriously naive!! Call it what you want 'informed intuition' or something bordering illegal - they're certainly far better informed than the average PI.
ihatemms
18/10/2012
22:37
Directors buy because it's part of their renumeration package. If they buy because of a known deal in the pipeline it's called 'insider trading' and is illegal.

When will you children learn?

gbb483
15/10/2012
16:29
Ah well the condition of our NHS is another matter, if the Chinese want to buy the blueprint that's up to them, I just liked the £400bn number...and us sharing some of it:)
paleje
12/10/2012
10:42
How soon before they inherit the NHS' ability to be bankrupt?
gbb483
12/10/2012
10:17
Today's FT - China's healthcare market £400bn within a decade.

Financial Times: Ken Clarke, the veteran Conservative politician, is to head a drive to sell expertise from the NHS to China – where the growing healthcare market is forecast to be worth £400 billion a year within the next decade.

paleje
03/9/2012
14:37
Once HMPL-004 patnering is confirmed(anytime now) these will hit £6 plus. Possible NAS listing for the drug division . The instists recently buying if you look at recent trades in the last 2-3 weeks.
ihatemms
03/9/2012
14:17
Panmure gave a buy recc 27/8/12. Much reduced EPS loss of -3.43p for 2013.
azalea
03/9/2012
12:29
So is today a dip to buy on, or a warning to get out?
gbb483
03/8/2012
09:17
Equity Development initiation note published this morning.

See for the full note.

Regards,

ED

hannahc
Chat Pages: Latest  32  31  30  29  28  27  26  25  24  23  22  21  Older

Your Recent History

Delayed Upgrade Clock